Short answer
LENZ Therapeutics, Inc. (LENZ) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3M (down 72.9% year over year) with net income of −$31M.
Q3 2026 key financials · XBRL
- Revenue
- $3M
- −72.9% YoY · −38.3% QoQ
- Net income
- −$31M
- −85.4% YoY · +3.0% QoQ
- Operating margin
- -972.8%
- EPS (diluted)
- −$0.99
- −67.8% YoY · +2.9% QoQ
Source: XBRL data from the LENZ Therapeutics, Inc. (LENZ) Q3 2026 10-Q on SEC EDGAR. USD.
LENZ Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $15.1M, versus $12.5M license revenue YoY, with $2.6M product sales
- Net loss $31.0M vs $16.7M YoY, with SG&A $35.8M vs $27.6M
- VIZZ product sales best-performing line: $2.6M from approximately 38,000 packs
- Cash, equivalents and marketable securities $197.3M; operating cash outflow $94.6M through nine months
- Strategic reorganization: approximately 75% headcount reduction, approximately $5M restructuring charges expected in fourth quarter 2026
Risk Factors
- New regulatory risk triggered by current administration: FDA staffing reductions and government shutdowns could delay reviews, inspections, and future approvals
- Most material commercial update: October 2026 reorganization prioritizing consumer marketing and reducing operating expenses
- Competitive risk: Ryzumvi approval in October 2026 adds another presbyopia treatment competitor
- Market-acceptance risk: VIZZ remains vulnerable to patient concerns about prescription burden and side effects versus reading glasses
- Financial risk: Net losses reached $104.4 million for nine months ended September 30, 2026, with accumulated deficit of $331.5 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LENZ Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.